Navigation Links
Pioneering research succeeds in producing industrially vital chemical through engineered bacteria
Date:8/26/2009

A team of South Korean scientists have succeeded in engineering the bacterium E. coli to produce the industrial chemical putrescine. The research, published in the journal Biotechnology and Bioengineering, provides a renewable alternative to the production of this important chemical which is traditionally created using fossil fuels.

Putrescine, a four carbon chain diamine, is an important platform chemical with a wide range of applications for the pharmaceutical, agrochemical and chemical industries. It is currently used to synthesize nylon-4,6, a widely used engineering plastic. Currently putrescine is priced at over 1,600 per ton with an estimated demand of 10,000 tons per year, which is expected to grow.

Currently the production of putrescine on an industrial scale relies on chemical synthesis, which requires non-renewable petrochemicals and expensive catalyst systems. This process is highly toxic and flammable with potentially severe repercussions for both the environment and human health. Now the Korean-based team, led by Professor Sang Yup Lee at KAIST, have pioneered the biotechnological production of the chemical using renewable materials.

"For the first time we have developed a metabolically engineered E. coli strain that efficiently produces putrescine," said Professor Lee. "The development of a bio-refinery for chemicals and materials is very important in a world where dependency on fossil fuels is an increasing concern."

The team developed a strain of E.coli capable of producing putrescine through metabolic engineering. This is where a cell's metabolic and regulatory networks are enhanced in order to increase production of a needed product.

First the team weakened or deleted competing metabolic pathways within the E.Coli strain before deleting pathways which cause putrescine degradation. They also amplified the crucial enzyme Spec C, which converts the chemical ornithine into putrescine. Finally the putrescine exporter, which allows excretion of intracellularly made putrescine, was engineered while a global regulator was engineered to further increase the concentration of putrescine. The final result of this process was an engineered E. coli strain which produced 24.2 g of putrescine per litre.

However, as it was believed that putrescine is toxic to microorganisms the team had to study putrescine tolerance in E. coli before it could be engineered to overproduce the chemical to the levels needed for industrial production.

The results revealed that E. coli can tolerate at least 0.5 M of putrescine, which is tenfold higher than the usual concentration in the cell. This level of tolerance was an important surprise as it means that E. coli can be engineered to overproduce putrescine to industrially competitive levels.

"The previously expected toxicity of putrescine may explain why its microbial production has been overlooked," said Lee. "Now a metabolically engineered E.coli strain has been developed which is capable of efficiently producing putrescine using renewable methods to an industrial level. This metabolic engineering framework should be useful for developing metabolically engineered microorganisms for the efficient production of other chemicals from renewable resources."


'/>"/>

Contact: Ben Norman
Benorman@wiley.com
44-012-437-70375
Wiley-Blackwell
Source:Eurekalert

Related biology technology :

1. Georgia Reproductive Specialists is First in Southeast to Offer Pioneering Test of Womens Biological Clock
2. NorthPoint Domain and Boston Medical Center Partner to Apply Advanced Patient Engagement Instruments to Pioneering Cardiac Robotic Surgery Program
3. Pioneering IVF Technique Produces Region's First Pregnancy
4. PAREXEL Expands Pioneering Asian Ethnobridging Expertise
5. Pioneering Cancer Center Introduces Advanced Varian RapidArc(TM) Treatments for Cancer Patients in Central Germany
6. Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000
7. DNA Software, Inc. Awarded $2.5 M in NIH Funding to Develop Pioneering Nucleic Acid-based Technologies
8. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
11. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... Clinical ... it has acquired the assets of Theorem Clinical Research - Clinical Supplies ... clinical trial drug packaging, labeling, storage, reconciliation, and distribution for pharmaceutical trials ...
(Date:12/6/2016)... 6, 2016  SRI International has been awarded ... the National Institutes of Health,s National Institute of ... AIDS (NIAID-DAIDS) to support the manufacturing and characterization ... agents. Under the seven-year contract, SRI will provide ... for candidate HIV-prevention products that emerge from investigator-initiated ...
(Date:12/5/2016)... 5, 2016 Axovant Sciences Ltd. (NYSE: ... on the treatment of dementia, today announced that data ... of Alzheimer,s disease will be presented at the 2016 ... December 9, 2016 in San Diego ... both simple and complex measures of activities of daily ...
(Date:12/5/2016)... ... December 05, 2016 , ... In anticipation of AxioMed’s exclusive ... production, company President, Jake Lubinski will be traveling to Germany on December 6th. ... Cologne and Karlsruhe to discuss the benefits of a viscoelastic total disc replacement. ...
Breaking Biology Technology:
(Date:12/6/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... of €500.0 million principal amount of its 1.414% senior unsecured ... 2.425% senior unsecured notes due 2026. The ... 2016, subject to the satisfaction of customary closing conditions.  The ... The Company intends to use the net ...
(Date:12/6/2016)... , Dec. 6, 2016 Valencell , the ... it has seen a third consecutive year of triple ... technology in 2016 with a 360 percent increase in ... This increase was driven by sales of its wrist ... interest in its technology for hearables for fitness and ...
(Date:12/6/2016)... , Dec. 6, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... announced today a five (5) year funding commitment ... to expand the rehabilitation and reentry support to ... History Established in 2004, the Prison Entrepreneurship Program ...
Breaking Biology News(10 mins):